EDOR®, Emotra’s method, is at the beginning of its initial commercialisation phase. Emotra’s success will strongly depend on the Company’s ability to gain acceptance for the concept at academically prestigious clinics in Sweden and around the world.
Our ongoing efforts to establish the method began at the end of 2012. An extensive international, clinical, multi-centre study, EUDOR-A, was initiated in 2014.
The study has been conducted through a collaboration between a total of 18 clinics/scientific institutes, the European Psychiatric Association’s Suicide Section, EPA-SS, and Emotra. During the testing period, which ended in the middle of March 2016, more than 1,500 patients were tested at 15 clinics. Since all patients need to be followed up for a full year after testing, we will be closing the study in the middle of March 2017. After closing it, we will commence our statistical calculations. On March 29–30, all of the centres will gather in Rome to discuss the study and its results. The aim of this meeting is to reach a consensus agreement on the method’s reliability and which benefits can be achieved by regularly testing with EDOR® in clinical practice.
When these internationally leading clinics are satisfied and prepared to openly act as ambassadors in support of our method, the groundwork for a wider penetration of first the Swedish, then international markets will be laid.
Emotra and EPA-SS have entered an agreement whereby all new training will be managed by EPA-SS using a number of experienced clinical specialists as teachers. There is no doubt that our market penetration will be facilitated by delegating these training efforts to EPA-SS and internationally opinion-leading psychiatric specialists.
Development and CE-marking of the product itself is complete. However, more work remains to be done before Emotra, within the area of CE-marking, will be able to maintain that the method can be used clinically to screen patients that are at risk of attempting suicide. Promising results from our clinical study, and most importantly a strongly positive consensus statement, are required if we are to be able to make such a claim.
The measurement curves from testing were previously analysed manually. Work with automating this analysis stage has come so far that a significant part of this analysis work can now be carried out by computer. Our continued software development will increase the method’s capacity.